Method of reducing TNF.alpha. levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines United States Patent 05635517

05635517 is referenced by 185 patents and cites 2 patents.

1-Oxo- and 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl) isoindolines substituted with amino in the benzo ring reduce the levels of TNF.alpha. in a mammal. A typical embodiment is 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-5-aminoisoindoline.

Title
Method of reducing TNF.alpha. levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines
Application Number
8/690258
Publication Number
5635517
Application Date
July 24, 1996
Publication Date
June 3, 1997
Inventor
Roger S C Chen
Edison
NJ, US
David I Stirling
Branchburg
NJ, US
George W Muller
Bridgewater
NJ, US
Agent
Mathews Collins Shepherd & Gould P A
Assignee
Celgene Corporation
NJ, US
IPC
C07D 401/04
A61K 31/445
View Original Source

Citations: 185 (view full list)

  1. Robert D Amato: Methods and compositions for inhibition of angiogenesis. The Children s Medical Center Corporation, Jones & Askew, January 27, 1998: US05712291 (142 worldwide citation)
  2. George W Muller, David I Stirling, Roger Shen Chu Chen: Isoindolines, method of use, and pharmaceutical compositions. Celgene Corporation, Mathews Collins Sherpherd & Gould, August 28, 2001: US06281230 (124 worldwide citation)
  3. George W Muller, David I Stirling, Roger Shen Chu Chen: Isoindolines, method of use, and pharmaceutical compositions. Celgene Corporation, Mathews Collins Shepherd & Gould P A, November 13, 2001: US06316471 (116 worldwide citation)
  4. George W Muller, David I Stirling, Roger Shen Chu Chen, Hon Wah Man: Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNF.alpha. levels. Celgene Corporation, Mathews Collins Shepherd & Gould P A, February 23, 1999: US05874448 (114 worldwide citation)
  5. Robert D&apos Amato: Methods and compositions for inhibition of angiogenesis by thalidomide. The Children&apos s Medical Center Corporation, Jones & Askew, May 22, 2001: US06235756 (73 worldwide citation)
  6. Robert J Hariri, David I Stirling, Laure A Moutouh De Parseval, Kyle W H Chan: Modulation of stem and progenitor cell differentiation, assays, and uses thereof. Anthrogenesis Corporation, Jones Day, March 3, 2009: US07498171 (55 worldwide citation)
  7. Jerome B Zeldis: Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes. Celgene Corporation, Jones Day, March 13, 2007: US07189740 (50 worldwide citation)
  8. Michael J Robarge, Roger Shen Chu Chen, George W Muller, Hon Wah Man: Isoindole-imide compounds, compositions, and uses thereof. Celgene Corporation, Jones Day, August 15, 2006: US07091353 (48 worldwide citation)
  9. Qing Liu, Henry Rendon Barragan, George Matcham: Umbilical cord biomaterial for medical use. Anthrogenesis Corporation, Jones Day, January 31, 2012: US08105634 (46 worldwide citation)
  10. Robert J Hariri, Janice M Smiell: Treatment of leg ulcers using placenta derived collagen biofabric. Anthrogenesis Corporation, Jones Day, April 19, 2011: US07928280 (43 worldwide citation)

References: 2

  1. Gilla Kaplan, Elisabeth P Sampaio: Method of treating abnormal concentrations of TNF .alpha.. The Rockefeller University, Mathews Woodbridge & Collins, January 31, 1995: US05385901 (109 worldwide citation)
  2. Tesfaye Biftu, Xiong Cai, Sajjet Hussion, Gurmit Grewal, T Y Shen: Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders. Cytomed, Cheryl K Kilpatrick & Cody Zalesky, October 31, 1995: US05463083 (39 worldwide citation)